In particular, NACT was effective in disease with more aggressive subtypes such as triple-negative, HER2-positive and high-grade breast cancer whereas steroid hormone receptor (HR) positive tumors responded weaker. This evidence concerns the gene ERBB2 and breast carcinoma.